AU2018302103B2 - Photodynamic therapy method for skin disorders - Google Patents

Photodynamic therapy method for skin disorders Download PDF

Info

Publication number
AU2018302103B2
AU2018302103B2 AU2018302103A AU2018302103A AU2018302103B2 AU 2018302103 B2 AU2018302103 B2 AU 2018302103B2 AU 2018302103 A AU2018302103 A AU 2018302103A AU 2018302103 A AU2018302103 A AU 2018302103A AU 2018302103 B2 AU2018302103 B2 AU 2018302103B2
Authority
AU
Australia
Prior art keywords
acne
pharmaceutical composition
skin
therapeutic method
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018302103A
Other languages
English (en)
Other versions
AU2018302103A1 (en
Inventor
Andrea Willey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65016221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018302103(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of AU2018302103A1 publication Critical patent/AU2018302103A1/en
Assigned to DUSA PHARMACEUTICALS, INC. reassignment DUSA PHARMACEUTICALS, INC. Request for Assignment Assignors: WILLEY, ANDREA
Application granted granted Critical
Publication of AU2018302103B2 publication Critical patent/AU2018302103B2/en
Priority to AU2024203899A priority Critical patent/AU2024203899A1/en
Assigned to SUN PHARMACEUTICAL INDUSTRIES, INC. reassignment SUN PHARMACEUTICAL INDUSTRIES, INC. Amend patent request/document other than specification (104) Assignors: DUSA PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A61N5/025—Warming the body, e.g. hyperthermia treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0625—Warming the body, e.g. hyperthermia treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
AU2018302103A 2017-07-17 2018-07-17 Photodynamic therapy method for skin disorders Active AU2018302103B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203899A AU2024203899A1 (en) 2017-07-17 2024-06-07 Photodynamic therapy method for skin disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762533558P 2017-07-17 2017-07-17
US62/533,558 2017-07-17
US201762534973P 2017-07-20 2017-07-20
US62/534,973 2017-07-20
PCT/US2018/042505 WO2019018408A1 (en) 2017-07-17 2018-07-17 METHOD OF PHOTODYNAMIC THERAPY AGAINST SKIN DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203899A Division AU2024203899A1 (en) 2017-07-17 2024-06-07 Photodynamic therapy method for skin disorders

Publications (2)

Publication Number Publication Date
AU2018302103A1 AU2018302103A1 (en) 2020-02-06
AU2018302103B2 true AU2018302103B2 (en) 2024-03-07

Family

ID=65016221

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018302103A Active AU2018302103B2 (en) 2017-07-17 2018-07-17 Photodynamic therapy method for skin disorders
AU2024203899A Pending AU2024203899A1 (en) 2017-07-17 2024-06-07 Photodynamic therapy method for skin disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203899A Pending AU2024203899A1 (en) 2017-07-17 2024-06-07 Photodynamic therapy method for skin disorders

Country Status (7)

Country Link
US (2) US20200261580A1 (enExample)
EP (1) EP3655035A4 (enExample)
JP (3) JP7454492B2 (enExample)
AU (2) AU2018302103B2 (enExample)
CA (1) CA3070107A1 (enExample)
IL (2) IL301904A (enExample)
WO (1) WO2019018408A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851161A1 (en) 2015-10-15 2021-07-21 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
WO2023079513A1 (en) 2021-11-05 2023-05-11 Dusa Pharmaceuticals, Inc. Photodynamic therapy illuminator devices and methods
JP2025537694A (ja) 2022-11-04 2025-11-20 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 光線力学的療法の方法
KR20250001702A (ko) * 2023-06-29 2025-01-07 주식회사 루트로닉 여드름 치료를 위한 레이저 치료 장치 및 이를 이용한 치료 방법
WO2025046471A1 (en) * 2023-08-28 2025-03-06 Sun Pharmaceutical Industries, Inc. Photodynamic therapy in combination with an hedgehog pathway inhibitor for use in treating non-melanoma skin cancer
WO2025235557A2 (en) 2024-05-07 2025-11-13 Sun Pharmaceutical Industries, Inc. Photodynamic therapy illuminator and photodynamic therapy methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090247932A1 (en) * 2008-04-01 2009-10-01 Daniel Barolet Method for the treatment of skin tissues
US20130274834A1 (en) * 2006-04-18 2013-10-17 Daniel Barolet Method for the treatment of skin tissues.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079262A (en) * 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5814008A (en) * 1996-07-29 1998-09-29 Light Sciences Limited Partnership Method and device for applying hyperthermia to enhance drug perfusion and efficacy of subsequent light therapy
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
GB0424833D0 (en) * 2004-11-10 2004-12-15 Photocure Asa Method
US20110224598A1 (en) * 2010-03-12 2011-09-15 Daniel Barolet Radiant near infrared light emitting diode exposure as skin preparation
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
GB0700580D0 (en) * 2007-01-11 2007-02-21 Photocure Asa Use
WO2009003173A1 (en) * 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodymanic therapy
JP5964322B2 (ja) * 2011-01-13 2016-08-03 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． 光増感剤の局所送達用医薬組成物及びその使用
US20140067024A1 (en) * 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
US10583307B2 (en) * 2013-01-23 2020-03-10 Transqtronics, Llc. Heating device and method of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274834A1 (en) * 2006-04-18 2013-10-17 Daniel Barolet Method for the treatment of skin tissues.
US20090247932A1 (en) * 2008-04-01 2009-10-01 Daniel Barolet Method for the treatment of skin tissues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAROLET, D. et al. "Radiant Near Infrared Light Emitting Diode Exposure as Skin Preparation to Enhance Photodynamic Therapy Inflammatory Type Acne Treatment Outcome" Lasers in Surgery and Medicine (2010) Vol.42 No.2, pages 171 to 178 *

Also Published As

Publication number Publication date
EP3655035A1 (en) 2020-05-27
JP2020527592A (ja) 2020-09-10
JP7734222B2 (ja) 2025-09-04
US20220354952A1 (en) 2022-11-10
IL272081A (en) 2020-03-31
WO2019018408A1 (en) 2019-01-24
CA3070107A1 (en) 2019-01-24
AU2018302103A1 (en) 2020-02-06
US20200261580A1 (en) 2020-08-20
IL301904A (en) 2023-06-01
JP7454492B2 (ja) 2024-03-22
JP2025176048A (ja) 2025-12-03
JP2024050723A (ja) 2024-04-10
AU2024203899A1 (en) 2024-06-27
EP3655035A4 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US20220354952A1 (en) Photodynamic therapy method for skin disorders
Wan et al. Current evidence and applications of photodynamic therapy in dermatology
Sakamoto et al. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy
Gold et al. Split‐face comparison of photodynamic therapy with 5‐aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage
Wang et al. Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China
Itkin et al. δ‐Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome
Wang et al. Topical ALA PDT for the treatment of severe acne vulgaris
Nguyen et al. An update on topical photodynamic therapy for clinical dermatologists
Fritsch et al. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods
Tao et al. Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris
US20100255080A1 (en) Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
Kim et al. Topical photodynamic therapy using intense pulsed light for treatment of actinic keratosis: clinical and histopathologic evaluation
Abrouk et al. Prospective study of intense pulsed light versus pulsed dye laser with or without blue light in the activation of PDT for the treatment of actinic keratosis and photodamage
Buggiani et al. Photodynamic therapy: off-label and alternative use in dermatological practice
Cai et al. Photodynamic therapy for facial actinic keratosis: a clinical and histological study in Chinese patients
Chen et al. Limitations of ALA-PDT as a reliable therapy for AK in clinical practice
de Andrade et al. Photodynamic therapy for non-melanoma skin cancer
Hommel et al. Photodynamic therapy (PDT)
Cho et al. Topical Methyl Aminolevulinate Photodynamic Therapy in Porokeratosis of Mibelli: An Alternative Treatment for a Refractory Disease
Palm et al. Aminolevulinic acid: actinic keratosis and photorejuvenation
Goldberg Cosmetic photodynamic therapy
Gold Lasers, Photodynamic Therapy, and the Treatment of Medical Dermatologic Conditions
Sidoroff Topical sensitization—oncologic indications—actinic keratoses
Cañueto et al. [[Translated aricle]] An Overview of Actinic Keratoses: Understanding Etiology, Diagnosis, and Treatment Approaches
Anstey Photodynamic therapy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DUSA PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): WILLEY, ANDREA